Get the Stockscreener App
3.4612
0.28%
-0.0688
Lantern Pharma Inc stock is traded at $3.4612, with a volume of 2,951.
It is down -0.28% in the last 24 hours and up +0.57% over the past month.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
See More
Previous Close:
$3.53
Open:
$3.53
24h Volume:
2,951
Relative Volume:
0.04
Market Cap:
$38.71M
Revenue:
-
Net Income/Loss:
$-19.25M
P/E Ratio:
-1.9445
EPS:
-1.78
Net Cash Flow:
$-17.87M
1W Performance:
+2.92%
1M Performance:
+0.57%
6M Performance:
-16.78%
1Y Performance:
-15.59%
1-Day Range:
$3.4613
$3.5889
1-Week Range:
$3.32
$3.59
52-Week Range:
$2.55
$6.118
Lantern Pharma Inc Stock (LTRN) Company Profile
Name
Lantern Pharma Inc
Sector
Industry
Phone
972-277-1136
Address
1920 MCKINNEY AVENUE, DALLAS, TX
Compare LTRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
3.4613 | 39.48M | 0 | -19.25M | -17.87M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.44 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.46 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
830.98 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.86 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.41 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-21 | Initiated | H.C. Wainwright | Buy |
Lantern Pharma Inc Stock (LTRN) Latest News
FDA grants orphan drug designation to Lantern Pharma’s LP-284 for sarcomas - Investing.com Nigeria
Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas - PharmiWeb.com
Lantern Pharma (LTRN) Secures Orphan Drug Designation for LP-284 - GuruFocus
Lantern Pharma Establishes New AI Centre Of Excellence, Agentic Labs Hub In Bengaluru - Voice Of HealthCare
Lantern Pharma Expands Global AI Footprint with Bengaluru Center of Excellence - eHealth Magazine
Lantern Pharma to Set Up AI Center of Excellence in Bengaluru to Scale RADR Platform - Digital Health News
Critical Comparison: Lantern Pharma (NASDAQ:LTRN) versus Praxis Precision Medicines (NASDAQ:PRAX) - Defense World
FDA Grants Orphan Drug Status to Lantern Pharma's Treatment for Sarcoma (LTRN) - GuruFocus
Lantern Pharma launches AI Center of Excellence in Bengaluru to scale precision drug discovery globally - Indian Pharma Post
Recap Report: Whats the outlook for Lantern Pharma Incs sectorQuarterly Risk Review & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Lantern Pharma establishes AI Centre of Excellence and Advanced Agentic Labs in Bengaluru - BioSpectrum India
History Review: Is Lantern Pharma Inc stock a hidden gemGap Up & Trade Opportunity Analysis Reports - baoquankhu1.vn
Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RAD - PharmiWeb.com
Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma Companies - 01net
Lantern Pharma IncEstablishes Ai Center Of Excellence In Bengaluru - TradingView — Track All Markets
Is Lantern Pharma Inc. stock a contrarian buyJuly 2025 Highlights & AI Forecasted Stock Moves - Улправда
Why Lantern Pharma Inc. stock attracts global investorsEarnings Date Calendar & Top Analyst Picks Available for Free - Улправда
Lantern Pharma (NASDAQ:LTRN) Stock Price Up 6.2% – What’s Next? - Defense World
What analysts say about Lantern Pharma Inc stockMarket Capitalization Trends & Superior Capital Growth - earlytimes.in
Lantern Pharma Inc Stock Analysis and ForecastMACD Histogram Signals & Fast Profit Trading Strategies - earlytimes.in
Is Lantern Pharma Inc a good long term investmentResistance Breakout Alerts & Learn to Trade with Real-Time Feedback - earlytimes.in
Sentiment Recap: Is Lantern Pharma Inc. stock a safe buy before earningsWeekly Profit Summary & Free Expert Approved Momentum Trade Ideas - moha.gov.vn
What Wall Street predicts for Lantern Pharma Inc. stock priceJuly 2025 Update & Verified Entry Point Signals - Улправда
Lantern Pharma’s AI Bet Needs 2026 Trial Wins - Finimize
What momentum indicators show for Lantern Pharma Inc. stockEarnings Miss & AI Optimized Trade Strategies - DonanımHaber
Why Lantern Pharma Inc. stock remains resilientNew Guidance & Target Return Focused Stock Picks - Улправда
Lantern Pharma (NASDAQ:LTRN) Shares Down 6.4% – Should You Sell? - Defense World
Lantern Pharma Earnings Notes - Trefis
Analyst Upgrade: Why Lantern Pharma Inc stock is rated strong buyTrade Entry Summary & Daily Chart Pattern Signals - moha.gov.vn
Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Daily Commercial
Lantern Pharma announces LP-184 clinical trial met all primary endpoints - MSN
Lake Street Remains a Buy on Lantern Pharma (LTRN) - The Globe and Mail
Lantern Pharma (NASDAQ: LTRN) Details Encouraging LP-184 Phase 1a Results Showing Durable Disease Control in Advanced Solid Tumors - Digital Journal
Will Lantern Pharma Inc. stock benefit from automationTreasury Yields & AI Forecasted Stock Moves - Newser
Will Lantern Pharma Inc. stock rally after Fed decisionsPortfolio Return Report & Low Volatility Stock Suggestions - Newser
Lantern Pharma advances AI-Driven cancer drug after successful Phase 1a trial - Proactive financial news
Lantern’s cancer drug LP-184 shows promise in phase 1a trial - Investing.com Australia
Lantern Pharma (LTRN) Advances with Promising Clinical Insights from Phase 1a Study - GuruFocus
Lantern Pharma reports additional positive LP-184 Phase 1a results showing durable disease control in heavily pre-treated advanced cancer patients - marketscreener.com
Lantern’s cancer drug LP-184 shows promise in phase 1a trial By Investing.com - Investing.com South Africa
Lantern Pharma Reports Positive Phase 1a Data For LP-184 In Advanced Solid Tumors - Nasdaq
Lantern Pharma Inc. (LTRN) Rises 9.5% in Pre-market: Amid Routine Trading - Stocks Telegraph
Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials - Yahoo Finance
Can Jai Balaji Industries Limited Sustain EPS Growth Under Competitive PressureMorning Star Patterns & Zero-Cost Stock Research by Professionals - earlytimes.in
Lantern Pharma Inc Stock (LTRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lantern Pharma Inc Stock (LTRN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kreis Leslie W. | 10% Owner |
Jun 13 '25 |
Sale |
3.09 |
40,000 |
123,600 |
49,957 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 12 '25 |
Sale |
3.38 |
60,647 |
204,987 |
51,860 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 11 '25 |
Sale |
3.40 |
950 |
3,230 |
54,746 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 10 '25 |
Sale |
3.40 |
16 |
54 |
54,791 |
| Kreis Leslie W. | 10% Owner |
Jun 12 '25 |
Sale |
3.38 |
60,647 |
204,987 |
51,860 |
| Kreis Leslie W. | 10% Owner |
Jun 11 '25 |
Sale |
3.40 |
950 |
3,230 |
54,746 |
| Kreis Leslie W. | 10% Owner |
Jun 10 '25 |
Sale |
3.40 |
16 |
54 |
54,791 |
| Fletcher Aaron G.L. | 10% Owner |
May 27 '25 |
Sale |
3.05 |
21,037 |
64,163 |
56,467 |
| Fletcher Aaron G.L. | 10% Owner |
May 29 '25 |
Sale |
3.03 |
20,200 |
61,206 |
54,792 |
| Fletcher Aaron G.L. | 10% Owner |
May 28 '25 |
Sale |
2.87 |
15,000 |
43,050 |
55,753 |
2.22%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):